Baoyuan Pharmaceutical and Cinda Bio-Announce Phase 2 Clinical Data of ROS1/NTRK Inhibitors

Text|Pharmaceutical Mission Hills

The 2021 Chinese Society of Clinical Oncology (CSCO) Annual Meeting is underway

Taletrectinib is a new generation of tyrosine kinase inhibitor (TKI) under development.

Taletrectinib was originally developed by Daiichi Sankyo, and Baoyuan Medicine obtained the exclusive global rights of the drug in 2018

In this CSCO, Baoyuan Pharmaceutical and Xinda Bio announced the preliminary results of a phase 2 study (TRUST study) of taletrectinib in the treatment of ROS1-positive non-small cell lung cancer

Among 21 patients who had not received crizotinib treatment, the confirmed objective response rate (ORR) was 90.

Among the 16 patients who had received crizotinib, the confirmed ORR was 43.

Among the 16 patients who had received crizotinib treatment, 3 patients were confirmed to be positive for the ROS1 G2032R resistance mutation.

Among patients with evaluable brain metastases before enrollment, the objective response rate in the brain assessed by the investigator was 83.

Taletrectinib is well tolerated, and treatment-related adverse events mainly include gastrointestinal adverse events and reversible aspartate aminotransferase (AST) and alanine aminotransferase (ALT) elevations

Reference materials:

[1] Cinda Biosciences and Baoyuan Pharmaceutical announced the interim data of the phase II trial of Taletrectinib in ROS1-positive non-small cell lung cancer at the CSCO annual meeting in 2021.

(The original text has been deleted)